Compare ServiceNow Inc (NOW) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Natera Inc. Common Stock — how do they compare? ServiceNow Inc trades at $140.64 (market cap $143.30B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: ServiceNow Inc is far larger — about 2.5× Natera Inc. Common Stock's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Natera Inc. Common Stock for 0 Days on average.
| NOW | NTRA | |
|---|---|---|
Market Cap | $143.30B | $57.03B |
Volume | 13,207,010 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $189.26 | $425.64 |
52-Week Low | $83.00 | $179.42 |
Typical Hold Time | 54 Days | 0 Days |
Enterprise Value | $147.09B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $140.32, down 0.38% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.90, and its AI business surpassed $1 billion in annual contract value. Revenue grew to $13.28 billion in 2025, with a net income margin of 11.34%, though valuation multiples remain elevated with a P/E of 86.63.
The outlook is positive, supported by robust AI adoption and enterprise demand, but risks include high valuation, competitive pressures, and potential margin compression. Analysts are overwhelmingly bullish with an 86.96% buy rating and a consensus price target of $150.71, suggesting upside potential from current levels.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
